Fig. 5: Neurofibromin therapeutic inhibitors and potential targets.
From: The therapeutic potential of neurofibromin signaling pathways and binding partners
The identification of key regulatory neurofibromin partners may have important clinical implications, in a strategy aimed at blocking its inactivation and/or upregulating the protein. These benefits may extend beyond therapies relevant to neurofibromin to serve as a potential clinical strategy to attenuate the Ras pathway in tumors harboring variants in genes that function upstream of Ras. Inhibitors and potential targets are shown in red.
